Therapeutic drug monitoring of cardioactive drugs

Dasgupta, Amitava; Krasowski, Matthew D.

doi:10.1016/b978-0-12-815849-4.00012-8

Cited by 5 publications

(11 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the interference of different drugs used as medical treatments for different common diseases was evaluated. To do that, a bovine serum containing 3.9 mM K + was spiked with a concentration of each drug slightly higher than the maximum therapeutic level expected in blood [36]. In this sense, Fig.…”

Section: Optimization Of the Poc Microanalyzermentioning

confidence: 99%

Serum/plasma potassium monitoring using potentiometric point-of-care microanalyzers with improved ion selective electrodes

Calvo-López

Arasa-Puig²,

Alonso-Chamarro³

et al. 2023

Talanta

View full text Add to dashboard Cite

Section: Optimization Of the Poc Microanalyzermentioning

confidence: 99%

Serum/plasma potassium monitoring using potentiometric point-of-care microanalyzers with improved ion selective electrodes

Calvo-López

Arasa-Puig²,

Alonso-Chamarro³

et al. 2023

Talanta

View full text Add to dashboard Cite

“…In this paper, paracetamol (acetaminophen) was chosen as a well-established analgesic to evaluate the dynamic profiles in human saliva. [21] The main goal of this work is to develop a universal protocol for analgesic TDM using a simple electrochemical device to monitor paracetamol physiological changes in undiluted saliva, in order to establish personalized temporal profiles after pills intake. Several electrochemical devices for paracetamol detection have been reported; [10,22,23] however, studies of paracetamol in saliva are scarce and the challenge of perform analysis in human saliva has not been addressed.…”

Section: Introductionmentioning

confidence: 99%

“…[3] Therapeutic drug monitoring (TDM) consists in tracking the drug levels in blood and/or plasma, or other bodily biofluids comparable to blood drug concentrations aiming individualized dose-response features of drugs. [3,5,9] Therapeutic studies have been made based on blood analysis for personalized TDM; however, it is nonviable owing to the costs with sampling, collecting, storage, transporting, processing, and analyzing in a centralized and specialized laboratory. [3,5,7] Non-invasive bodily biofluids such as sweat, [10] tears, [11] interstitial fluid, [12] breath [13] and saliva [11] are excellent alternatives to be used instead of invasive TDM.…”

mentioning

confidence: 99%

On‐Site Therapeutic Drug Monitoring of Paracetamol Analgesic in Non‐Invasively Collected Saliva for Personalized Medicine

Gomes

Raymundo‐Pereira

2023

Small

View full text Add to dashboard Cite

effects on the treatment, causing side effects. [4,5,8] Given the fluctuations in the interpatient drugs exposures, personalized prescriptions are a promising strategy to maximize the therapeutic drugs effectiveness. [3,5] Of special importance in recent years, "precision medicine" has been proposed as a new strategy designed at personalizing the dosage toward enhanced therapeutic efficacy and minimal deleterious drug effects. [3] Therapeutic drug monitoring (TDM) consists in tracking the drug levels in blood and/or plasma, or other bodily biofluids comparable to blood drug concentrations aiming individualized dose-response features of drugs. [3,5,9] Therapeutic studies have been made based on blood analysis for personalized TDM; however, it is nonviable owing to the costs with sampling, collecting, storage, transporting, processing, and analyzing in a centralized and specialized laboratory. [3,5,7] Non-invasive bodily biofluids such as sweat, [10] tears, [11] interstitial fluid, [12] breath [13] and saliva [11] are excellent alternatives to be used instead of invasive TDM. [5] Of particular importance, saliva emerges as a valuable biological fluid for TDM purpose offering advantages such as: i) reflects the free analyte levels; ii) saliva is easier to collect than blood without patient stimulation; and iii) patients prefer saliva sampling over blood sampling. Moreover, the analytical tools can be easily designed for analysis of saliva specimens. [6,14,15] Several analytical techniques have been used to analyze the concentration of drugs in TDM. However, these techniques rely on costly and bulky instruments as such as high-performance liquid chromatography (HPLC) that is unsuitable for decentralized analysis requiring skilled personnel. [5,6,15] Saliva-based electrochemical sensors have paved the way for on-site TDM by tracking drug concentrations. [3] Sensors and biosensors have been used to detect Vitamin C, [11] antibiotics, [16] Vitamin C and D, [17] irinotecan and doxorubicin, [18] and Levodopa. [7] With biosensors, high specificity can be achieved; however, the issues with storage, stability, and high cost with enzymes and antibodies remain. Hence, detection of therapeutic drugs for on-site monitoring should be conducted with non-enzymatic sensors [19] in which they can provide costeffective, rapid response, and on-site analysis for TDM. [20] They are more reliable due to high stability, robustness, and Paracetamol or acetaminophen is the main non-opioid analgesic recommended for mild pain by the World Health Organization (WHO) analgesic ladder. However, the high levels used of paracetamol are associated with the hepatotoxicity and nephrotoxicity caused by accumulation of toxic metabolites. The sensor is produced on a polyester substrate containing a full electrochemical device with working, auxiliary, and reference electrodes in which, guiding personalized medicine solutions are not reported. Temporal paracetamol profiles in human saliva are performed with the subject taking different amounts of commercial...

show abstract

“…In addition, the development of novel antibiotics has currently stagnated, 5 highlighting the importance of optimizing conventional antimicrobial treatments. Aminoglycoside antibiotics, which exhibit concentration-dependent bactericidal activity against a wide range of Gram-negative pathogens, 6 have received renewed attention for AMR treatment. However, owing to the characteristic adverse reactions of nephrotoxicity and ototoxicity that require therapeutic drug monitoring (TDM), the use of aminoglycosides was previously strictly restricted.…”

mentioning

confidence: 99%

“…Amikacin is one of the most commonly used aminoglycosides. 6,9,10 To maximize the therapeutic effect of amikacin, certain guidelines recommend considering the ratio of its peak concentration to the minimum inhibitory concentration (MIC) as a pharmacokinetic/pharmacodynamic (PK/PD) index and monitoring trough concentrations to minimize nephrotoxicity. 9,11 However, in critically ill patients, managing the peak and trough concentrations within an appropriate range is challenging because of the increased volume of distribution and highly variable drug clearance.…”

mentioning

confidence: 99%

A simulation study on model‐informed precision dosing of amikacin for achieving target area under the concentration–time curve

Yamada,

Oda,

Nishihara

et al. 2024

Brit J Clinical Pharma

View full text Add to dashboard Cite

AimsAmikacin requires therapeutic drug monitoring for optimum efficacy; however, the optimal model‐informed precision dosing strategy for the area under the concentration–time curve (AUC) of amikacin is uncertain. This simulation study aimed to determine the efficient blood sampling points using the Bayesian forecasting approach for early achievement of the target AUC range for amikacin in critically ill patients.MethodsWe generated a virtual population of 3000 individuals using 2 validated population pharmacokinetic models identified using a systematic literature search. AUC for each blood sampling point was evaluated using the probability of achieving a ratio of estimated/reference AUC at steady state in the 0.8–1.2 range.ResultsOn day 1, the 1‐point samplings for population pharmacokinetic models showed a priori probabilities of 26.3 and 45.6%, which increased to 47.3 and 94.4% at 23 and 15 h, respectively. Using 2‐point sampling at the peak (3 and 4 h) and trough (24 h) on day 1, these probabilities further increased to 72.3 and 99.5%, respectively. These probabilities were comparable on days 2 and 3, regardless of 3 and 6 sampling points or estimated glomerular filtration rate. These results indicated the higher predictive accuracy of 2‐point sampling than 1‐point sampling on day 1 for amikacin AUC estimation. Moreover, 2‐point sampling was a more reasonable approach than rich sampling.ConclusionsThis study contributes to the development of an efficient model‐informed precision dosing strategy for early targeting of amikacin AUC in critically ill patients.

show abstract

Therapeutic drug monitoring of cardioactive drugs

Cited by 5 publications

References 83 publications

Serum/plasma potassium monitoring using potentiometric point-of-care microanalyzers with improved ion selective electrodes

Serum/plasma potassium monitoring using potentiometric point-of-care microanalyzers with improved ion selective electrodes

On‐Site Therapeutic Drug Monitoring of Paracetamol Analgesic in Non‐Invasively Collected Saliva for Personalized Medicine

A simulation study on model‐informed precision dosing of amikacin for achieving target area under the concentration–time curve

Contact Info

Product

Resources

About